// App-Quantinova.ai

12548 : 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) Treatment Decreases Epicardial and Pericardial Adipose Tissue in Patients with Recent Acute Coronary Syndrome

Researchers

Presenter

  • Vahid Nabavi Larijani

Principal Investigators

  • Ferdinand R Flores

  • Jean-Claude Tardif

  • Sachidanand Prabhu

  • Nina Ram

  • Michael Baskett

  • Armand Ardestani

  • Naser Ahmadi

  • Jean Gregoire

  • Josephine Pressacco

  • Matthew Budoff

Medical Centers

  • Los Angeles Biomedical Res Inst at Harbor-UCLA Medical Ctr, Los Angeles, CA

  • Montreal Heart Institute, Montreal, Quebec, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Acute Coronary Syndromes

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • Atreleuton

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • NCT00358826

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved